Thanks for the invitation! Lung cancer is the malignant tumor with the highest incidence rate at present. Lung cancer is subdivided into non-small cell lung cancer and small cell lung cancer, with non-small cell lung cancer accounting for 80% and small cell lung cancer accounting for 20%. Overall, non-small cell lung cancer is less malignant than small cell lung cancer because small cell lung cancer is easy to metastasize in the early stage, the disease progresses rapidly, there are fewer drugs available, and the mortality rate is high. Non-small cell lung cancer is mainly subdivided into squamous lung cancer and lung adenocarcinoma, what is the difference between them?

At present, the incidence rate of lung adenocarcinoma is slightly higher than that of squamous lung cancer, and in terms of treatments, lung adenocarcinoma is more selective. In recent years, the hot targeted therapy drugs such as Eresa and Trocar are mainly used for lung adenocarcinoma with EGFR mutation, and the effect is also very good. On the other hand, there are fewer targeted therapies available for squamous lung cancer, and the efficacy is slightly worse, basically only relying on chemotherapy. However, the survival of patients with squamous lung cancer varies greatly, with some progressing faster and some progressing more slowly, depending on the individual!

To summarize:

Tumor is a very heterogeneous disease, and survival varies greatly among different patients. Lung adenocarcinoma has more treatments than squamous lung cancer, but there is no clear-cut statement about which is more serious, and I personally feel that the overall survival of lung adenocarcinoma patients is better than that of squamous lung cancer patients.

Tumor is a very heterogeneous disease, and survival varies greatly among different patients. Lung adenocarcinoma has more therapeutic means than squamous lung cancer, but there is no clear statement about which one is more serious. I personally feel that the overall survival of lung adenocarcinoma patients is better than that of squamous lung cancer patients.